The Goldman Sachs Group Lowers LivaNova (NASDAQ:LIVN) Price Target to $63.00

LivaNova (NASDAQ:LIVNGet Rating) had its price objective dropped by equities research analysts at The Goldman Sachs Group from $73.00 to $63.00 in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 17.27% from the stock’s previous close.

A number of other research analysts also recently commented on the stock. Needham & Company LLC dropped their price objective on shares of LivaNova from $88.00 to $77.00 and set a “buy” rating for the company in a research note on Wednesday, November 2nd. StockNews.com upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Sunday, November 6th. TheStreet cut LivaNova from a “c-” rating to a “d” rating in a report on Wednesday, October 19th. Finally, Piper Sandler cut their price objective on LivaNova from $94.00 to $84.00 in a report on Wednesday, November 2nd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $83.00.

LivaNova Stock Up 0.2 %

Shares of NASDAQ LIVN opened at $53.72 on Wednesday. The firm has a market cap of $2.88 billion, a P/E ratio of -30.70 and a beta of 0.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.53 and a current ratio of 2.96. LivaNova has a 1 year low of $41.82 and a 1 year high of $89.69. The firm’s 50 day moving average price is $49.42 and its 200 day moving average price is $57.88.

LivaNova (NASDAQ:LIVNGet Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.01. The business had revenue of $252.60 million for the quarter, compared to analysts’ expectations of $246.53 million. LivaNova had a positive return on equity of 9.28% and a negative net margin of 9.14%. As a group, sell-side analysts anticipate that LivaNova will post 1.73 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently modified their holdings of the stock. State of Alaska Department of Revenue lifted its position in shares of LivaNova by 2.3% during the second quarter. State of Alaska Department of Revenue now owns 7,666 shares of the company’s stock worth $478,000 after purchasing an additional 175 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in LivaNova by 29.7% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 787 shares of the company’s stock valued at $49,000 after buying an additional 180 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of LivaNova by 2.3% during the second quarter. Exchange Traded Concepts LLC now owns 8,214 shares of the company’s stock valued at $513,000 after acquiring an additional 188 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of LivaNova by 1.9% during the third quarter. Oregon Public Employees Retirement Fund now owns 15,580 shares of the company’s stock worth $791,000 after acquiring an additional 287 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of LivaNova by 1.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 28,970 shares of the company’s stock worth $1,810,000 after acquiring an additional 308 shares in the last quarter. Institutional investors and hedge funds own 98.89% of the company’s stock.

About LivaNova

(Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Articles

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.